STOCK TITAN

PDS Biotechnology (NASDAQ: PDSB) CEO takes interim finance role as CFO departs

(Moderate)
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

PDS Biotechnology Corp (PDSB) reported that Lars Boesgaard resigned as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, effective September 12, 2026, to pursue other professional endeavors. He acknowledged that his resignation is not due to any disagreement regarding operations, policies, or practices.

Effective the same date, the board appointed Janetta Trochimiuk, the company’s Controller, as interim Principal Accounting Officer and Frank Bedu-Addo, Ph.D., President and Chief Executive Officer, as interim Principal Financial Officer. Ms. Trochimiuk, age 63, has over 25 years of experience in senior finance roles and will continue as Controller with an annual base salary of $279,519.57, remaining eligible for equity awards under the Third Amended and Restated 2014 Equity Incentive Plan.

Positive

  • None.

Negative

  • CFO, Principal Financial Officer and Principal Accounting Officer resigns effective September 12, 2026, representing a significant change in PDSB’s senior financial leadership despite no stated disagreements.

Filing Explained

Janetta Trochimiuk received no equity award in connection with becoming interim Principal Accounting Officer; her continuing eligibility for future equity awards is not an award, so the disclosed transition does not itself add a reported equity issuance.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Effective resignation date September 12, 2026 Effective date of Lars Boesgaard’s resignation from CFO, Principal Financial Officer and Principal Accounting Officer roles
Board appointment date August 19, 2026 Date the board appointed interim Principal Accounting Officer and interim Principal Financial Officer
Executive age 63 Age of interim Principal Accounting Officer, Janetta Trochimiuk
Experience in finance roles More than 25 years Length of Ms. Trochimiuk’s experience as a Controller or Chief Financial Officer
Base salary $279,519.57 per year Annual base salary for interim Principal Accounting Officer Janetta Trochimiuk
Par value per share $0.00033 per share Par value of PDS Biotechnology Corporation common stock
Principal Financial Officer financial
"as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer"
The principal financial officer is the senior executive who runs a company's financial operations: preparing and certifying financial reports, managing accounting controls, budgets and cash flow, and advising on financial strategy. Investors care about this role because its competence affects how trustworthy the company’s numbers are, how well it manages risk and capital needs, and the credibility of forecasts—like the chief navigator steering a firm's financial course.
Principal Accounting Officer financial
"appointed Janetta Trochimiuk ... as interim Principal Accounting Officer"
The Principal Accounting Officer is the person responsible for making sure a company's financial records are accurate and follow the rules. They play a key role in preparing financial reports that show how well the company is doing. This helps investors, managers, and regulators trust the company's financial information.
Controller financial
"the Company’s Controller, as interim Principal Accounting Officer"
Equity Incentive Plan financial
"eligible for equity awards under the Company’s Third Amended and Restated 2014 Equity Incentive Plan"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.

FAQ

What leadership change did PDSB announce regarding its CFO on August 13, 2026?

PDSB announced that Lars Boesgaard resigned as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, effective September 12, 2026. He stated the decision was to pursue other professional endeavors and not due to disagreements with the company.

Who will serve as interim Principal Financial Officer at PDSB (PDSB) after September 12, 2026?

PDSB appointed Frank Bedu-Addo, Ph.D., its President and Chief Executive Officer, as interim Principal Financial Officer effective September 12, 2026. This consolidates both CEO and principal finance responsibilities in one executive on an interim basis.

Who is PDSB’s interim Principal Accounting Officer and what is her background?

PDSB named Janetta Trochimiuk as interim Principal Accounting Officer effective September 12, 2026. She is age 63, has over 25 years of experience as Controller or CFO, and has served as the company’s Controller since December 2019.

What is the annual base salary of PDSB’s interim Principal Accounting Officer?

Interim Principal Accounting Officer Janetta Trochimiuk will continue to receive a base salary of $279,519.57 per year. She also remains eligible for equity awards under PDSB’s Third Amended and Restated 2014 Equity Incentive Plan.

Did PDSB’s departing CFO cite any disagreements with the company?

No. Lars Boesgaard acknowledged that his resignation from PDSB is not the result of any disagreement relating to the company’s operations, policies, or practices, and is instead to pursue other professional endeavors.

Does PDSB’s interim Principal Accounting Officer receive new equity awards for her promotion?

No. The filing states that Janetta Trochimiuk did not receive any equity awards in connection with her promotion, although she remains eligible for equity grants under the company’s existing 2014 Equity Incentive Plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549


FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 13, 2026


 
PDS BIOTECHNOLOGY CORPORATION
(Exact Name of Registrant as Specified in Charter)

Delaware
001-37568
26-4231384
 
 
 
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
303A College Road East, Princeton, NJ 08540
(Address of Principal Executive Offices, and Zip Code)
(800) 208-3343
Registrant’s Telephone Number, Including Area Code



(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   

Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   

Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which
Registered
Common Stock, par value $0.00033 per share
PDSB
The Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Yes No



Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 13, 2026, Lars Boesgaard submitted his resignation, effective as of September 12, 2026, as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer of PDS Biotechnology Corporation (the “Company”) in order to pursue other professional endeavors. Mr. Boesgaard acknowledged that his resignation is not the result of any disagreement relating to Company’s operations, policies or practices.

On August 19, 2026, the board of directors of the Company appointed Janetta Trochimiuk, the Company’s Controller, as interim Principal Accounting Officer and Frank Bedu-Addo, Ph.D., the Company’s President and Chief Executive Officer, as interim Principal Financial Officer, each effective as of September 12, 2026.

Ms. Trochimiuk, age 63, joined the Company as Controller in December 2019. Ms. Trochimiuk has more than 25 years of experience as a Controller or Chief Financial Officer at various corporations. Prior to joining the Company, Ms. Trochimiuk served as Controller at Delcath Systems, Inc., located in New York, New York from April 2017 to July 2019, Controller and Chief Financial Officer of Westwood Consulting Group, LLC from October 2012 to January 2017, regional Chief Financial Officer at Ceragon Networks, Inc. from January 2009 to October 2012, and Controller North America at Olam Americas, Inc. from November 2005 to September 2007. Ms. Trochimiuk holds a Bachelor of Business Administration from Bernard M. Baruch College and is a licensed CPA.

There are no family relationships between Ms. Trochimiuk and any of the Company’s directors or other executive officers. There are no arrangements or understandings between Ms. Trochimiuk and any other persons or entities pursuant to which she has been appointed as interim Principal Accounting Officer.

Ms. Trochimiuk will continue to receive a base salary of $279,519.57 per year and will continue to be eligible for equity awards under the Company’s Third Amended and Restated 2014 Equity Incentive Plan. Ms. Trochimiuk did not receive any equity awards in connection with her promotion.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
PDS BIOTECHNOLOGY CORPORATION
 
 
Date: August 19, 2026
By: /s/ Frank Bedu-Addo, Ph.D.
 
Name: Frank Bedu-Addo, Ph.D.
 
Title: President and Chief Executive Officer



Filing Exhibits & Attachments

3 documents